Literature DB >> 23509050

Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.

Gail A Spiridigliozzi, James H Heller, Priya S Kishnani, Ans T Van der Ploeg, B J Ebbink, F K Aarsen, C M van Gelder, J M P Van den Hout.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23509050     DOI： 10.1212/WNL.0b013e31828b8af0

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?

Authors:  A Broomfield; J Fletcher; P Hensman; R Wright; H Prunty; J Pavaine; S A Jones
Journal:  JIMD Rep       Date:  2017-07-20

2.  Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease.

Authors:  J Hordeaux; L Dubreil; C Robveille; J Deniaud; Q Pascal; B Dequéant; J Pailloux; L Lagalice; M Ledevin; C Babarit; P Costiou; F Jamme; M Fusellier; Y Mallem; C Ciron; C Huchet; C Caillaud; M-A Colle
Journal:  Acta Neuropathol Commun       Date:  2017-09-06       Impact factor: 7.801

3.  Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement.

Authors:  Matteo Paoletti; Anna Pichiecchio; Giovanna Stefania Colafati; Giorgio Conte; Federica Deodato; Serena Gasperini; Francesca Menni; Francesca Furlan; Laura Rubert; Fabio Maria Triulzi; Claudia Cinnante
Journal:  Front Neurol       Date:  2020-11-25       Impact factor: 4.003

4.  Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes.

Authors:  Yunli Zhou; Mi Zhang; Dan He; Xueyuan Hu; Huarong Xiong; Jianyong Wu; Biyue Zhu; Jingqing Zhang
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.